Choose your Region

Are you sure you want to proceed?

You will be leaving the Cook Medical website that you were viewing and going to a Cook Medical website for another region or country. Not all products are approved in all regulatory jurisdictions. The product information on these websites is intended only for licensed physicians and healthcare professionals.

September 10th, 2019

New Cook Medical paclitaxel data presented at CIRSE confirms safety of Zilver® PTX®

Barcelona, Spain — Michael D. Dake, MD, presented at the Cardiovascular and Interventional Radiological Society of Europe (CIRSE) conference regarding new data on the use of Zilver® PTX®, Cook Medical’s paclitaxel-coated stent for peripheral arterial disease (PAD).

Dr. Dake is the senior vice president of health sciences at the University of Arizona, Tucson, and is president-elect of the Society of Interventional Radiology Executive Council. At CIRSE, Dr. Dake presented new 5-year data on Zilver PTX that Cook Medical gathered from the randomized controlled trial (RCT) performed to obtain FDA approval. Dr. Dake was also the global principal investigator for the study.

Cook Medical is the only organization that has publicly provided long-term patient-level data on the use of paclitaxel-coated devices for PAD. In addition to previously released information, the presentation included new data that had not been previously published. This new data includes information from patients who had not previously completed the study, such as those who had been lost to follow up, giving a more complete view of how paclitaxel-coated devices affect patients. The data confirms no significant difference in all-cause mortality for the Zilver PTX drug-eluting stent compared to traditional angioplasty or a bare metal stent (BMS). The findings further show that treatment with Zilver PTX and paclitaxel dose were not predictors of mortality. However, age and other serious conditions common in PAD patients were associated with mortality.

The findings that Dr. Dake presented have been published online in CardioVascular and Interventional Radiology (CVIR), a peer-reviewed journal. You can read the publication here.

“Our clinical program evaluates the Zilver PTX technology across a broad, real-world patient population—including patients at high risk for restenosis and reintervention. Zilver PTX offers proven long-term benefits that help patients get back to living,” said Mark Breedlove, vice president of Cook Medical’s Vascular division.

If you have questions about Zilver PTX, please contact us at, and a member of our team will respond within 24 hours. The patient-level data used for the RCT analysis, as well as Dr. Dake’s presentation and other Zilver PTX information, is available at

Dr. Michael Dake is a paid consultant for Cook Medical.

About Cook Medical
Since 1963, Cook Medical has worked closely with physicians to develop technologies that eliminate the need for open surgery. Today we are combining medical devices, biologic materials and cellular therapies to help the world’s healthcare systems deliver better outcomes more efficiently. We have always remained family owned so that we have the freedom to focus on what we care about: patients, our employees and our communities. Find out more at, and for the latest news, follow us on TwitterFacebook and LinkedIn.